-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Chronicle of events
Events

MXIS DEVELOPMENT TARGET
2024
Milestones of innovative drugs and new quality
August: Application for production of the new anti influenza drug Mapasvir;
TSLP monoclonal antibody completes the first phase II subject enrollment
October: The first subject enrolled in phase II of GSNOR inhibitor was completed
November: The first subject enrolled in Phase II of the MABA dual target project was completed
December: PREP oral COPD project received IND clinical approval
2022
Accelerate the research and development of innovative drugs and high-end complex formulations, and promote the process of globalization
On September 2, 2022, after being recommended by the National Health Commission, the National Medical Products Administration organized a discussion and agreed to accept the use of Likang V-01
Emergency use of sequential enhanced immunization against novel coronavirus.
On September 26th, the group successfully listed and issued Global Depositary Receipts (GDRs) on the Swiss Stock Exchange, becoming the first domestic biopharmaceutical company to issue GDRs in Switzerland and accelerating the process of globalization.
On October 15th, the group's first independently developed tobramycin inhalation solution (i.e. Jianketuo) ®) Formally approved for listing, it also announced the birth of the first inhaled antibiotic in China and even globally. We will change the current situation of no available medication in the field of nebulized inhalation therapy for patients with bronchiectasis in China, and provide more support for patients with bronchiectasis.
From 2018
Layout high-end complex formulation technology platform, inhalation formulation platform stands out
In April 2019, Shutalin ® The first generic of compound ipratropium bromide inhalation solution has been approved for marketing, becoming the first inhalation preparation approved for marketing since the national generic drug consistency evaluation;
As of April 2022, Jiankangyuan has been approved to launch 5 varieties covering 4 categories and a total of 9 product specifications, establishing its leading position in domestic inhalation formulations.
As of October 2022, 7 varieties of Jiankangyuan have been approved for listing, covering 4 categories and a total of 11 product specifications.
2010-2015
Active participation in biomedical and layout of Internet One Health industry
In 2010, Monoclonal Antibody Biology Co., Ltd. was established. In the same year, it joined the TNC Greater China Council. It actively utilized the company's superior resources, integrated resources and participated in the natural environmental protection work. In 2015, it laid out the Internet Medical One Health industry.
2002-2003
The Group covered dual-listed companies through expansion and acquisition
In 2002, it acquired Livzon Pharmaceutical Group; in 2003, it was renamed Joincare Pharmaceutical Group Industry Co., Ltd.
2001-2002
Landing in the capital market
In 2001, Taitai Pharmaceutical Industry was listed on the Shanghai Stock Exchange successfully, issued 70 million shares, and raised 1.7 billion yuan. It was the A-shares listed to raise funds leading private enterprises at that time.
1995-1997
Successful transformation
In 1995, the company realized the strategic transformation and entered the pharmaceutical industry, and changed its name to “Shenzhen Taitai Pharmaceutical Industry Co., Ltd.”;
In 1997, the company acquired Shenzhen Haibin Pharmaceutical Co., Ltd., completing the successful transformation from a health product company to a pharmaceutical company.
1992-1994
Establishment in the South
In 1992, Shenzhen Aimier Food Co., Ltd., the predecessor of Joincare Pharmaceutical Group Industry Co., Ltd., was established;
In 1993, the first brand for women “Taitai Oral Liquid” was successfully launched, creating the era of women's health products and laying a foundation of the company’s leading position in the health products industry.
In 1994, the company changed its name to “Shenzhen Taitai Health Food Co., Ltd.”;
Quick Navigation
+86 755-33268688 | Service Hotline

Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home